Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial

Hum Reprod. 2005 Mar;20(3):611-5. doi: 10.1093/humrep/deh663. Epub 2004 Dec 9.

Abstract

Background: The aim of this study was to evaluate the effect of doubling the starting dose of gonadotrophins on the ovarian response in IVF patients with a low antral follicle count (AFC).

Methods: Fifty-two patients with an AFC of <5 follicles of 2-5 mm diameter before starting their first IVF cycle participated in this randomized controlled trial. They were randomized by opening a sealed envelope, receiving either 150 IU (group I, n = 26) or 300 IU (group II, n = 26) of rFSH as a starting dose. The main outcome measures of the study were number of oocytes, poor response (<4 oocytes at retrieval or cancellation due to insufficient follicle growth) and ongoing pregnancy (12 weeks of gestation).

Results: The groups were comparable regarding patient characteristics and outcome of the IVF treatment. The median number of oocytes collected was 3 for both groups (P = 0.79). The difference in the mean number of oocytes was 0.3 oocytes in favour of group I (P=0.69). Sixty-five per cent of the patients in group I experienced a poor response and 62% in group II. The ongoing pregnancy rate was 8% in group I and 4% in group II (P = 0.55).

Conclusions: Expected poor response patients, defined as patients with an AFC <5, are likely not to benefit from a higher starting dose of gonadotrophins in IVF.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Cell Count
  • Dose-Response Relationship, Drug
  • Female
  • Fertilization in Vitro / methods*
  • Follicle Stimulating Hormone / administration & dosage*
  • Follicle Stimulating Hormone / therapeutic use
  • Humans
  • Oocytes / cytology
  • Ovarian Follicle / diagnostic imaging*
  • Pregnancy
  • Pregnancy Rate
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use
  • Tissue and Organ Harvesting
  • Treatment Failure
  • Ultrasonography

Substances

  • Recombinant Proteins
  • Follicle Stimulating Hormone